Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction

被引:23
|
作者
Zhuang, Chunlin [1 ]
Miao, Zhenyuan [1 ]
Zhu, Lingjian [1 ]
Zhang, Yongqiang [1 ]
Guo, Zizhao [1 ]
Yao, Jianzhong [1 ]
Dong, Guoqiang [1 ]
Wang, Shengzheng [1 ]
Liu, Yang [1 ]
Chen, Hai [1 ]
Sheng, Chunquan [1 ]
Zhang, Wannian [1 ]
机构
[1] Second Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China
关键词
p53-MDM2; Small molecule inhibitors; Thio-benzodiazepine; Antitumor activity; IN-VIVO; P53; MDM2; ANTAGONISTS; DISCOVERY; DRUG; ACTIVATION; STRATEGY; DESIGN; CANCER;
D O I
10.1016/j.ejmech.2011.09.043
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of thio-benzodiazepine p53-MDM2 inhibitors were designed and synthesized based on the principle of bioisosterism. Most of the thio-benzodiazepines had nanomolar to micromolar affinity toward MDM2. Particularly, compounds 8a (K-i = 0.52 mu M) and 8f (K-i = 0.32 mu M) showed binding activity comparable to the positive drug nutlin-3a (K-i = 0.23 mu M). Meanwhile, compound 8j exhibited excellent antitumor activity against the U-2 OS human osteosarcoma cell line with an IC50 value of 1.06 mu M, which was about 23 times higher than that of nutlin-3a. The docking model also successfully predicted that this class of compounds mimicked three p53 critical residues binding to MDM2. The thio-benzodiazepines represent a promising class of non-peptide inhibitors of the p53-MDM2 interaction. (C) 2011 Published by Elsevier Masson SAS.
引用
收藏
页码:5654 / 5661
页数:8
相关论文
共 50 条
  • [41] Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
    Zhu, Haohao
    Gao, Hui
    Ji, Yingying
    Zhou, Qin
    Du, Zhiqiang
    Tian, Lin
    Jiang, Ying
    Yao, Kun
    Zhou, Zhenhe
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [42] p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents
    Nayak, Surendra Kumar
    Khatik, Gopal L.
    Narang, Rakesh
    Monga, Vikramdeep
    Chopra, Harish Kumar
    CURRENT CANCER DRUG TARGETS, 2018, 18 (08) : 749 - 772
  • [43] Inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.
    Hardcastle, IR
    Ahmed, SU
    Barrett, PA
    Endicott, JA
    Golding, BT
    Griffin, RJ
    Gruber, J
    Hutton, C
    Kemp, SJ
    Lunec, J
    Noble, ME
    Riedinger, C
    Smyth, LA
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9053S - 9054S
  • [44] Identification of substituted isoindolinones as potent inhibitors of the MDM2-p53 protein-protein interaction
    Watson, Anna
    Liu, Junfeng
    Armstrong, Elizabeth
    Blackburn, Timothy
    Endicott, Jane A.
    Golding, Bernard T.
    Griffin, Roger J.
    Lu, Xiaohong
    Newell, David R.
    Noble, Martin E. M.
    Riedinger, Christiane
    Lunec, John
    Hardcastle, Ian R.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [45] MDM2-p53 protein-protein interaction inhibitors: A-ring substituted isoindolinones
    Watson, Anna F.
    Liu, Junfeng
    Bennaceur, Karim
    Drummond, Catherine J.
    Endicott, Jane A.
    Golding, Bernard T.
    Griffin, Roger J.
    Haggerty, Karen
    Lu, Xiaohong
    McDonnell, James M.
    Newell, David R.
    Noble, Martin E. M.
    Revill, Charlotte H.
    Riedinger, Christiane
    Xu, Qing
    Zhao, Yan
    Lunec, John
    Hardcastle, Ian R.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (19) : 5916 - 5919
  • [46] Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors
    Si, Dongjuan
    Luo, Huijuan
    Zhang, Xiaomeng
    Yang, Kundi
    Wen, Hongmei
    Li, Wei
    Liu, Jian
    BIOORGANIC CHEMISTRY, 2021, 115
  • [47] Design, synthesis and biological evaluation of novel potent MDM2/p53 small-molecule inhibitors
    Ivanenkov, Yan A.
    Vasilevski, Sergei V.
    Beloglazkina, Elena K.
    Kukushkin, Maksim E.
    Machulkin, Alexey E.
    Veselov, Mark S.
    Chufarova, Nina V.
    Chernyaginab, Elizaveta S.
    Vanzcool, Anton S.
    Zyk, Nikolay V.
    Skvortsov, Dmitry A.
    Khutornenko, Anastasia A.
    Rusanov, Alexander L.
    Tonevitsky, Alexander G.
    Dontsova, Olga A.
    Majouga, Alexander G.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (02) : 404 - 409
  • [48] Design and synthesis of dual inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions
    Adhikari, Santosh
    Cano, Celine
    Golding, Bernard
    Hardcastle, Ian
    Harnor, Suzannah
    Jennings, Claire
    Lunec, John
    Myers, Stephanie
    Newell, D.
    Reeks, Judith
    Shouksmith, Andrew
    Tudhope, Sue
    Wedge, Steve
    Willmore, Elaine
    Wittner, Anita
    Zhao, Yan
    Griffin, Roger
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [49] Improvement of the synthesis and pharmacokinetic properties of chromenotriazolopyrimidine MDM2-p53 protein-protein inhibitors
    Beck, Hilary P.
    DeGraffenreid, Michael
    Fox, Brian
    Allen, John G.
    Rew, Yosup
    Schneider, Stephen
    Saiki, Anne Y.
    Yu, Dongyin
    Oliner, Jonathan D.
    Salyers, Kevin
    Ye, Qiuping
    Olson, Steven
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (09) : 2752 - 2755
  • [50] Mathematical Simulation of p53-Mdm2 Protein Biological System Regulation
    Voropaeva, O. F.
    Shokin, Yu. I.
    Nepomnyashchikh, L. M.
    Senchukova, S. R.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2014, 157 (04) : 535 - 538